Scarica l'app Stockscreener
7.9127
3.30%
0.2527
Precedente Chiudi:
$7.66
Aprire:
$7.77
Volume 24 ore:
9,740
Relative Volume:
0.27
Capitalizzazione di mercato:
$561.84M
Reddito:
-
Utile/perdita netta:
$-2.97M
Rapporto P/E:
-8.0088
EPS:
-0.988
Flusso di cassa netto:
$-1.18M
1 W Prestazione:
+45.99%
1M Prestazione:
-12.37%
6M Prestazione:
-50.55%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$7.41
$8.3506
Intervallo di 1 settimana:
$5.40
$8.77
Portata 52W:
$5.40
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
7.967 | 540.19M | 0 | -2.97M | -1.18M | -0.988 |
VRTX
Vertex Pharmaceuticals Inc
|
456.62 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.68 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.57 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
696.51 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
149.55 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Yd Bio Ltd Borsa (YDES) Ultime notizie
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
YD Bio details roadmap for integrated oncology ecosystem - TipRanks
YD Bio (YDES) CEO details direct and indirect share stakes - Stock Titan
Collective Metals Initiates Inaugural Drill Program at the Rocas Uranium Project in Southeast Athabasca Basin - The Manila Times
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem - Bitget
Inside YD Bio’s plan to link cancer detection with immunotherapy - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - Defense World
NMFC PE Ratio & Valuation, Is NMFC Overvalued - Intellectia AI
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - Defense World
YD Bio (NASDAQ: YDES) registers 11.5M warrant shares; announces Taiwan-U.S. FDA alliance - Stock Titan
YD Bio Forms Taiwan-U.S. Dual-Core FDA Regulatory Platform in Alliance with YC Biotech - TipRanks
YD Bio (Nasdaq: YDES) builds Taiwan-U.S. FDA regulatory platform - Stock Titan
YD Bio partners with YC Biotech to establish Taiwan-US dual-core regulatory platform - BioSpectrum Asia
YD Bio Says US Unit Selected as FDA Liaison for YC Biotech's Asia Clients - marketscreener.com
Yd Bio Limited announces strategic partnership with Yc Biotech Co - marketscreener.com
SunPower to Participate in the 38th Annual ROTH Conference - The Manila Times
Rumble App Now Includes Rumble Shorts on iPhones Following Apple Approval - The Manila Times
The Chefs’ Warehouse, Inc. to Participate in the UBS Global Consumer & Retail Conference - The Manila Times
Freshworks to Participate in Upcoming Investor Conferences - The Manila Times
The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March - The Manila Times
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Major Shareholder Announcement - The Manila Times
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform - marketscreener.com
Inside YD Bio’s new Taiwan‑U.S. gateway for FDA drug and device approvals - Stock Titan
YDESYD Bio Ltd Latest Stock News & Market Updates - Stock Titan
Ethan Shen holds 77.06% of YD Bio Ltd (YDES) as amended ownership filing - Stock Titan
YD Bio Ltd (YDES) PE Ratio (TTM) Chart - GuruFocus
YD Bio Shares Spark Retail Trader Buzz Following Nasdaq Debut via Breeze SPAC - MSN
CMB.TECH to Release Q4 2025 Earnings on February 26, 2026 - Intellectia AI
CMB.TECH Sells Two VLCCs, Realizing $98.2 Million Gain - Intellectia AI
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million By Investing.com - Investing.com Nigeria
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal By Investing.com - Investing.com South Africa
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal - Investing.com Canada
YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership - Nasdaq
YD Bio enters into binding LOI to acquire shares, assets of SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million - Investing.com
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy - The Manila Times
Cancer detection firm YD Bio targets $26.87M glioblastoma cell therapy deal - stocktitan.net
Diabetic Macular Edema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotech - Barchart.com
YD Bio Limited Announces Directorate Changes - marketscreener.com
YDES Stock Price, News & Analysis - Stock Titan
YD Bio Limited (YDES) board reshaped by majority holders’ written consent - Stock Titan
YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations. - Research Tree
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal - Investing.com Australia
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal By Investing.com - Investing.com South Africa
How an AI cancer test in Taipei hospitals could help shape future drugs - Stock Titan
YD Bio Limited entered into a Memorandum of Understanding to acquire EG BioMed Co., Ltd. - MarketScreener
YD Bio advances cancer detection and eye disease platforms By Investing.com - Investing.com Australia
Yd Bio Ltd Azioni (YDES) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):